Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | F2R | P25116 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.40 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.40 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13106368 | 0.87 | MAPT (0.49) | MAPTMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL589194 | 0.86 | MAPT (0.48) | MAPTMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL27566549 | 0.83 | MAPT (0.46) | MAPTMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL28996878 | 0.81 | MAPT (0.51) | MAPTMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL588588 | 0.79 | MAPT (0.53) | MAPTMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL22473631 | 0.78 | MAPT (0.51) | MAPTMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL2842932 | 0.77 | MAPT (0.48) | MAPTMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL588388 | 0.76 | L3MBTL1 (0.42) | MAPTMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL27546495 | 0.75 | MAPT (0.49) | MAPTMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL13106411 | 0.75 | L3MBTL1 (0.49) | MAPTMEN1KMT2ALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2311825-B1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2015-10-07 | — | — | EP | disclosed |
| US-20120277258-A1 | Chemical Compounds | LEO OSPREY LIMITED (JE) | 2012-11-01 | — | — | US | disclosed |
| US-8114885-B2 | Pazopanib hydrochloride and synthesis, chemical intermediates, and dosage forms thereof; anticancer; colon cancer, breast cancer | GLAXOSMITHKLINE LLC (US) | 2012-02-14 | — | — | US | disclosed |
| EP-2311825-A1 | Pyrimidineamines as angiogenesis modulators | GlaxoSmithKline LLC (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7858626-B2 | Pyrimidineamines as angiogenesis modulators | GLAXOSMITHKLINE LLC (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100105712-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-04-29 | — | — | US | disclosed |
| EP-1343782-B1 | PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS | SMITHKLINE BEECHAM CORP (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20070292513-A1 | CHEMICAL COMPOUNDS | NOVARTIS AG (CH) | 2007-12-20 | — | — | US | disclosed |
| US-20070270427-A1 | CHEMICAL COMPOUNDS | NOVARTIS AG (CH) | 2007-11-22 | — | — | US | disclosed |
| US-7262203-B2 | Pyrimidineamines as angiogenesis modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-28 | — | — | US | disclosed |
| CN-1307173-C | Pyrimidinamines as angiogenesis modulators | GLAXO GROUP LTD (GB) | 2007-03-28 | — | — | CN | disclosed |
| US-20070015756-A1 | Chemical compounds | NOVARTIS AG (CH) | 2007-01-18 | — | — | US | disclosed |
| US-7105530-B2 | inhibitors of vascular endothelial growth factor receptor-2 kinase; pazopanib and salts; for proliferative retinopathy; anticancer | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-20040242578-A1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | disclosed |
| CN-1549813-A | Pyrimidinamines as angiogenesis modulators | — | 2004-11-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242578-A1 | Pyrimidineamines as angiogenesis modulators | TYMS, TYMP, DPYD | MAPT 3924/4885MEN1 4640/4885KMT2A 1430/4885 |
| US-20070015756-A1 | Chemical compounds | KDR, FLT4, FLT1 | MAPT 3547/4885MEN1 3177/4885KMT2A 1583/4885 |
| US-20100105712-A1 | CHEMICAL COMPOUNDS | KDR, FLT4, FLT1 | MAPT 3547/4885MEN1 3177/4885KMT2A 1583/4885 |
| US-20120277258-A1 | Chemical Compounds | KDR, FLT4, FLT1 | MAPT 3547/4885MEN1 3177/4885KMT2A 1583/4885 |
| US-20070270427-A1 | CHEMICAL COMPOUNDS | KDR, FLT4, FLT1 | MAPT 3547/4885MEN1 3177/4885KMT2A 1583/4885 |
| US-20070292513-A1 | CHEMICAL COMPOUNDS | KDR, FLT4, FLT1 | MAPT 3547/4885MEN1 3177/4885KMT2A 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.